Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Alcohol-associated hepatitis (AH) is a severe form of alcohol-associated liver disease.
• It is characterized by high short-term mortality and a lack of effective treatments.

Purpose of the Study:

• To review the mechanisms underlying AH pathogenesis.
• To evaluate past and emerging clinical trials for targeted therapeutic development.

Main Methods:

• Synthesis of mechanistic insights into AH.
• Evaluation of clinical trial data for various therapeutic targets.

Main Results:

• AH pathogenesis involves hepatotoxicity, oxidative stress, inflammation, impaired regeneration, and gut-liver axis disruption.
• Previous trials targeting inflammation or apoptosis showed no survival benefit and raised safety concerns.
• Emerging therapies focus on mitigating oxidative stress, enhancing regeneration, and restoring gut integrity, including agents like IL-22, G-CSF, probiotics, FMT, larsucosterol, and FXR agonists.

Conclusions:

• Understanding AH biology provides a basis for mechanism-based therapeutic strategies.
• Integrating hepatology with addiction medicine and using stratified trial designs are crucial for advancing effective treatments.